Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
BioNTech, BMS tout first global data for PD-L1xVEGF drug in SCLC
BioNTech and BMS have picked the pumitamig dose for the Rosetta Lung-01 phase 3 trial in first-line extensive-stage small cell lung cancer.
Angus Liu
Sep 8, 2025 11:00am
BioNTech's ADC beats Roche’s Kadcyla in breast cancer phase 3
Sep 5, 2025 7:30am
Sino Biopharm buys Merck’s PD-1xVEGF bispecific partner LaNova
Jul 15, 2025 10:16am
Biokin, having landed BMS deal, posts ph. 3 bispecific ADC win
Jul 2, 2025 9:53am
NextCure advances ADC pivot with $745M deal for phase 1 drug
Jun 16, 2025 9:52am
To Gilead's new CMO, pipeline diversification is key
Jun 9, 2025 10:00am
